CD22 and acute lymphoblastic leukemia: Outcomes for CD22 CAR-T cells in adult relapsed/refractory large B-cell lymphoma have also been favorable.18 Since CD22 density is much higher in HCL/HCLv compared with B-ALL (median 44,000 v 3,500 sites/cell), and since Moxe achieved high rates of MRD-negative CR without selection for CD22 dim/negative HCL cells, we tested anti-CD22 CAR-T in HCL/HCLv to evaluate toxicity and determined whether responses would be deep and durable without CD22 antigen escape.